Repare Therapeutics (RPTX) Expected to Announce Quarterly Earnings on Wednesday

Repare Therapeutics (NASDAQ:RPTX) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Repare Therapeutics Stock Performance

RPTX stock opened at $1.28 on Wednesday. The firm has a 50 day simple moving average of $1.39 and a 200 day simple moving average of $2.58. Repare Therapeutics has a 52 week low of $1.10 and a 52 week high of $7.45. The stock has a market cap of $54.41 million, a P/E ratio of -0.64 and a beta of 0.88.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RPTX shares. Stifel Nicolaus decreased their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research report on Friday, November 8th. Finally, Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.